A Phase II Study of Pioglitazone for patients with cancer of the pancreas


This is an open label, single arm Phase 2 study. We plan to enroll 15 patients with adenocarcinoma of the pancreas to this study of oral pioglitazone 45 mg daily. Patients are allowed to continue on antineoplastic therapy while on this study and this will be determined by the treating physician

Participant Eligibility

1. Histologically proven adenocarcinoma of the pancreas
2. Radiologically measureable disease
3. ECOG functional status 0-2
4. Signed informed consent